Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Delivery of PARP inhibitors through 2HG-incorporated liposomes for synergistically targeting DNA repair in cancer

Cancer Letters(2024)10.1016/j.canlet.2024.217268Source: DataRank Database

Delivery of PARP inhibitors through 2HG-incorporated liposomes for synergistically targeting DNA repair in cancer is a research paper published in Cancer Letters (2024). On theSindex it has a DataRank of 0. It has been cited 6 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

6 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 1.24)OA: closedTopics (57)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (10)

Yixian Huang ORCID,Shangyu Chen ORCID,Bei Zhang ORCID,Haozhe Huang ORCID,Sheida Dabiri

Live enrichment

PubMed:39321912 OpenAlex:https://openalex.org/W4402734822

NIH

Grant: 1S10OD030254-01A1

Olympus FV3000 Confocal Microscope

NIH

Grant: R01CA223788

NIH

Grant: R01CA219399

NIH

Grant: RO1CA270623

NIH

Grant: RO1CA278608

FWCI

1.24

Citation Percentile

0.8%

Citation Trend

2025

2026

closedLicense: Elsevier TDM

publisherhttps://api.elsevier.com/content/article/PII:S0304383524006633?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0304383524006633?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.canlet.2024.217268

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39321912

Fields of Study

PARP inhibition in cancer therapyDNA Repair MechanismsAdvanced Electron Microscopy Techniques and Applications03 medical and health sciences0302 clinical medicineLiposomesHumansPoly(ADP-ribose) Polymerase InhibitorsAnimalsBenzimidazolesCell Line, TumorDNA RepairXenograft Model Antitumor AssaysFemaleMiceDrug SynergismNeoplasmsBRCA1 Protein

MeSH Terms

Poly(ADP-ribose) Polymerase InhibitorsAnimalsBenzimidazolesDNA RepairDrug SynergismFemaleHumansLiposomesNeoplasmsBRCA1 ProteinXenograft Model Antitumor AssaysCell Line, TumorMice

Keywords

Poly ADP ribose polymeraseLiposomeCancer researchPARP inhibitorDNA repairDNA damageCancerDNAChemistryMedicineBiologyBiochemistryGeneticsPolymeraseBRCA1 ProteinDrug SynergismPoly(ADP-ribose) Polymerase InhibitorsXenograft Model Antitumor AssaysMiceCell Line, TumorNeoplasmsLiposomesHumansAnimalsBenzimidazolesFemale

Sustainable Development Goals

SDG 0: Good health and well-being

Delivery of PARP inhibitors through 2HG-incorporated liposomes for synergistically targeting DNA repair in cancer

FAIR Checklist

Authors (10)

Funding (5 grants)

Impact

Open Access

Topics